PTJ
MREO

Paul Tudor Jones’s Mereo BioPharma MREO Stock Holding History

Paul Tudor Jones’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-26,179
Closed -$86.4K – 2618
2024
Q1 		$86.4K Buy
+26,179
New +$88.6K ﹤0.01% 2100

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Paul Tudor Jones's MREO Position: Q2 2024 in Review

Paul Tudor Jones sold out of Mereo BioPharma (MREO) in Q2 2024, closing a stake of 26,179 shares — an estimated $86.4K sold.

Paul Tudor Jones first reported a position in MREO in Q1 2024 and held it in 1 quarter. The position peaked at $86.4K in Q1 2024. 79 funds tracked by Wall St. Rank hold MREO as of Q2 2024.

  • Paul Tudor Jones reported no remaining Mereo BioPharma position as of Q2 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 26,179 Mereo BioPharma shares in Q2 2024, an estimated $86.4K.
  • Paul Tudor Jones first reported a position in Mereo BioPharma in Q1 2024 and held it in 1 quarter.
  • Paul Tudor Jones's Mereo BioPharma position peaked at $86.4K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2024.

Based on Tudor Investment Corp's 13F filing for Q2 2024, filed 14 Aug 2024.